Previously, a phase I/II study of pamiparib monotherapy reported an ORR of 64.6% in previously treated advanced platinum-sensitive ovarian cancer [24], while in the germline BRCA1/2 mutated platinum-sensitive relapsed ovarian cancer cohort of the MEDIOLA trial the ORR was 71.9% with olaparib plus durvalumab [46]. The gene discussed is BRCA1; the disease is ovarian cancer.